الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Summary and conclusion
Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development resulting in accumulation of undifferentiated and functionally heterogeneous populations of cells that interfere with the production of normal blood cells.
The prediction for AML had been improved tremendously in the past decades. However, accurate risk- stratification at diagnosis or prognosis remained difficult.
Cytarabine (Ara-C) is the primary drug in different treatment schemas for acute myeloid leukemia (AML) and requires the human equilibrative nucleoside transporter (HENT1) to enter cells and low expression levels of these genes may affect the rate of response to this drug.
In order to further investigate the prognosis of acute myeloid leukemia, the expression human equilibrative nucleoside transporter (HENT1) level in 40 acute myeloid leukemia (AML) and 20 controls using Real-Time Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RTQ-PCR) was measured aiming to show human equilibrative nucleoside transporter (HENT1) gene expression pattern in acute myeloid leukemia patients and its role in disease severity and over all time.
HENT-1 was expressed in 30%(12/40) of AML cases and 10% (2/20) in controls cases. Our results showed a correlation between the appearance of the gene and the over all survive which the patients show positive(HENT1) have a higher survival rate (91.7%) than patients with negative (HENT1) gene have a lower survival rate (85.7%) .
The results also showed a correlation between gene appearance and response rate of treatment, which patients show positive (HENT1) gene had a higher rate of complete recovery (29%) than the patients show negative (HENT1) gene had lower rate of complete recovery and treatment response (25%).
We conclude that the gene appearance (HENT1) is highly correlated with ability to survive and the rate of response to treatment and that the gene (HENT1 )gene may represent a new therapeutic approach to treat acute leukemia.